Streetbeat News

Analyst Ratings

STRO

JMP Securities has reiterated a Market Outperform rating for Sutro Biopharma (NASDAQ:STRO) and maintained a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 2:20 pm

IBEX

Baird analyst David Koning has maintained an Outperform rating on IBEX and raised the price target from $20 to $23.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 2:19 pm

MNMD

Canaccord Genuity has maintained its Buy rating on Mind Medicine (NASDAQ:MNMD) but has lowered the price target from $16 to $14.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 2:19 pm

VLO

Goldman Sachs analyst Neil Mehta maintains a Sell rating on Valero Energy and lowers the price target from $149 to $131.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 2:17 pm

MRNA

Goldman Sachs analyst Salveen Richter maintains a Buy rating on Moderna but lowers the price target from $178 to $139.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 2:15 pm

FDS

FactSet Research Systems Inc. (NYSE:FDS) is expected to report higher Q4 earnings with analysts projecting $3.62 per share, up from $2.93 last year, and revenue of $546.81 million. Analysts have revised their forecasts, with mixed ratings ranging from Underweight to Sector Perform.

Portfolio Pulse from Avi Kapoor

September 16, 2024 | 2:14 pm

PRLD

JMP Securities has reiterated its Market Outperform rating for Prelude Therapeutics, maintaining a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 2:14 pm

NVMI

Nova shares fell after Citigroup downgraded the stock from Buy to Neutral and reduced its price target from $273 to $224.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 2:13 pm

MMSI

Wells Fargo analyst Larry Biegelsen maintains an Equal-Weight rating on Merit Medical Systems (NASDAQ:MMSI) and raises the price target from $85 to $103.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 2:13 pm

REAL

Northland Capital Markets has initiated coverage on RealReal (NASDAQ:REAL) with an Outperform rating and set a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 2:12 pm